PLX News and Press, Protalix BioTherapeutics Inc. From 10/09/23

2023-10-09 08:23:30 ET More on InMode, Mirati Therapeutics, etc. InMode: Bullish Support Failed To Materialize InMode: Strong Net Cash Position Sets The Stage For Opportunistic Buybacks InMode: Be Greedy When Others Are Fearful Bristol-Myers Squibb to acquire...

Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel PR Newswire CARMIEL, Israel , Oct. 9, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production...

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors PR Newswire Appointment effective as of September 14, 2023; Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel , Sept. ...

2023-09-06 08:12:04 ET Summary Protalix BioTherapeutics reported Q2 2023 revenues of $35.08 million, a 300.72% YoY increase, beating Wall Street estimates. The US FDA approved PLX's Elfabrio for the treatment of Fabry disease in adults, expanding its commercialization target. ...

Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire CARMIEL, Israel , Sept. 6, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on t...

2023-08-08 11:23:45 ET What Are Penny Stocks? Penny stocks are shares of companies trading for under $5. They generally are the stock of companies in early or development stages that are typically smaller in size. While the vast majority of penny stocks trade on the OTC market or &#...

2023-08-07 14:08:45 ET Investors often rely on stock market news to stay abreast of everything, ranging from low-cost penny stocks to industry giants such as Apple or Tesla. It’s no secret that news can ignite excitement and skepticism in the blink of an eye, fueling speculation ...

2023-08-07 10:10:22 ET Protalix BioTherapeutics, Inc. (PLX) Q2 2023 Earnings Conference Call August 07, 2023 08:30 A.M. ET Company Participants Charles Padala - IR Dror Bashan - President and CEO Eyal Rubin - SVP and CFO Conference Call Participants B...

2023-08-07 06:54:22 ET Protalix BioTherapeutics press release ( NYSE: PLX ): Q2 GAAP EPS of $0.21 beats by $0.25 . Revenue of $35.08M (+300.9% Y/Y) beats by $24.86M . Cash and cash equivalents were approximately $48.2 million at June 30, 2023. F...

Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results PR Newswire Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , Aug. 7, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE Amer...